看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
. ]6 W' h" p F+ o
* \+ V/ }" T1 K# @& k6 r# R; w6 I* A) I) P
Currently available feasibility data for possible combination strategies. 6 ]$ v+ h$ R; Y9 [" l& @# m/ q
————————————————————————————————
0 K( C$ b9 e" S( s; iCombination Feasibility according to preliminary data
' T; J) X1 U: E$ q) ?——————————————————————————————————
) d) b7 a3 ^1 F; E) tBevacizumab + sorafenib Yes, reduced dose
" o' a) f. H0 H. R% a) {+ V+ |Bevacizumab + sunitinib† No
6 b* q+ W# j. G/ a1 LBevacizumab + temsirolimus Yes
8 L9 z2 }5 e7 ?7 X* `Bevacizumab + everolimus Yes ) } I! d4 H3 l( s1 N
Sorafenib + sunitinib ?
( H5 g5 R6 O# C- @Sorafenib + temsirolimus Yes, reduced dose ( N9 }; o M- y0 _
Sorafenib + everolimus Yes, reduced dose # @: _( @$ I; M) r% b* h. n- D
Sunitinib + temsirolimus† No
3 M# J, R D8 V9 R3 KSunitinib + everolimus ? 6 p* J& q+ c6 D! u$ H
Temsirolimus + everolimus ?
. Y. F* n: ]' K, N7 Y9 \————————————————————
# S' t& k2 D. F/ ]4 u†Led to US FDA warning.8 {6 V. R' }+ l5 M
?: As yet unattempted combination.
& `1 @( p& f$ t, n) C" r0 K |